Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control?

References

• Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet15, 702–703 (1964).
   Web of Science ®Google Scholar
• Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat. Rev. Cancer4(10), 757–768 (2004).
   PubMed Web of Science ®Google Scholar
• Rapp CE, Hewetson JF. Infectious mononucleosis and the Epstein–Barr virus. Am. J. Dis. Child132(1), 78–86 (1978).
   PubMedGoogle Scholar
• Macsween KF, Crawford DH. Epstein–Barr virus – recent advances. Lancet Infect. Dis.3(3), 131–140 (2003).
   PubMed Web of Science ®Google Scholar
• Williams H, Crawford DH. Epstein–Barr virus: the impact of scientific advances on clinical practice. Blood107(3), 862–869 (2006).
   Google Scholar
• Nye FJ. Social class and infectious mononucleosis. J. Hyg. (Lond.)71(1), 145–149 (1973).
   PubMedGoogle Scholar
• Schuster V, Kreth HW. Epstein–Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects. Eur. J. Pediatr.151(10), 718–725 (1992).
   PubMed Web of Science ®Google Scholar
• Auwaerter PG. Infectious mononucleosis in middle age (clinical conference). JAMA281(5), 454–459 (1999).
   PubMed Web of Science ®Google Scholar
• Crawford DH, Swerdlow AJ, Higgins C et al. Sexual history and Epstein–Barr virus infection. J. Infect. Dis.186(6), 731–736 (2002).
   PubMedGoogle Scholar
• Crawford DH, Macsween KF, Higgins CD et al. A cohort study among university students: identification of risk factors for Epstein–Barr virus seroconversion and infectious mononucleosis. Clin. Infect. Dis.43(3), 276–282 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas R, Macsween KF, McAulay K et al. Evidence of shared Epstein–Barr viral isolates between sexual partners, and low level EBV in genital secretions. J. Med. Virol.78(9), 1204–1209 (2006).
   PubMedGoogle Scholar
• Morris MC, Edmunds WJ. The changing epidemiology of infectious mononucleosis? J. Infect.45(2), 107–109 (2002).
   PubMedGoogle Scholar
• Tattevin P, Le Tulzo Y, Minjolle S et al. Increasing incidence of severe Epstein–Barr virus-related infectious mononucleosis: Surveillance study. J. Clin. Microbiol.44(5), 1873–1874 (2006).
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Tanaka-Taya K, Kazuyama Y et al. Prevalence of Epstein–Barr virus in Japan: trends and future prediction. Pathol. Int.56(3), 112–116 (2006).
   PubMedGoogle Scholar
• Sitki-Green DL, Edwards RH, Covington MM, Raab-Traub N. Biology of Epstein–Barr virus during infectious mononucleosis. J. Infect. Dis.189(3), 483–492 (2004).
   PubMedGoogle Scholar
• Puchhammer-Stockl E, Gorzer I. Cytomegalovirus and Epstein–Barr virus subtypes – the search for clinical significance. J. Clin. Virol.36(4), 239–248 (2006).
   PubMedGoogle Scholar
• Thorley-Lawson DA, Mann KP. Early events in Epstein–Barr virus infection provide a model for B cell activation. J. Exp. Med.162(1), 45–59 (1985).
   PubMed Web of Science ®Google Scholar
• Pattengale PK, Smith RW, Perlin E. Atypical lymphocytes in acute infectious mononucleosis. Identification by multiple T and B lymphocyte markers. N. Engl. J. Med.291(22), 1145–1148 (1974).
   PubMed Web of Science ®Google Scholar
• Callan MF, Steven N, Krausa P et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med.2(8), 906–911 (1996).
   PubMed Web of Science ®Google Scholar
• Silins SL, Sherritt MA, Silleri JM et al. Asymptomatic primary Epstein–Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood98(13), 3739–3744 (2001).
   PubMedGoogle Scholar
• Balfour HH Jr, Holman CJ, Hokanson KM et al. A prospective clinical study of Epstein–Barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis.192(9), 1505–1512 (2005).
   PubMed Web of Science ®Google Scholar
• Williams H, Macsween K, McAulay K et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J. Infect Dis.190(1), 63–71 (2004).
   PubMed Web of Science ®Google Scholar
• Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol.170(5), 2590–2598 (2003).
   PubMed Web of Science ®Google Scholar
• Williams H, McAulay K, Macsween KF et al. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol.129(2), 266–274 (2005).
   PubMed Web of Science ®Google Scholar
• Corsi MM, Ruscica M, Passoni D, Scarmozzino MG, Gulletta E. High Th1-type cytokine serum levels in patients with infectious mononucleosis. Acta Virol.48(4), 263–266 (2004).
   PubMedGoogle Scholar
• Helminen M, Lahdenpohja N, Hurme M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein–Barr virus infection. J. Infect. Dis.180(2), 496–499 (1999).
   PubMed Web of Science ®Google Scholar
• Clute SC, Watkin LB, Cornberg M et al. Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein–Barr virus-associated infectious mononucleosis. J. Clin. Invest.115(12), 3602–3612 (2005).
   PubMedGoogle Scholar
• Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein–Barr virus replication strategies. Rev. Med. Virol.15(1), 3–15 (2005).
   PubMed Web of Science ®Google Scholar
• Fafi-Kremer S, Morand P, Brion JP et al. Long-term shedding of infectious Epstein–Barr virus after infectious mononucleosis. J. Infect. Dis.191(6), 985–989 (2005).
   PubMed Web of Science ®Google Scholar
• Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein–Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol.78(10), 5194–5204 (2004).
   PubMed Web of Science ®Google Scholar
• Schooley RT. Epstein–Barr virus (infectious mononucleosis). In: Principles and Practice of Infectious Diseases, 4th Edition. Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingston Inc., New York, NY, USA, 1364–1377 (1995).
   Google Scholar
• Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein–Barr virus infections: biology, pathogenesis, and management. Ann. Intern. Med.118(1), 45–58 (1993).
   PubMed Web of Science ®Google Scholar
• Generalfeatures of infectious mononucleosis (roundtable discussion). In: Infectious Mononucleosis: Proceedings of Symposium. Glade PR (Ed.), JB Lippincott, New York, NY, USA, 1–18 (1973).
   Google Scholar
• Auwaerter PG. Infectious mononucleosis: return to play. Clin. Sports Med.23(3), 485–497 (2004).
   PubMedGoogle Scholar
• Murray BJ. Medical complications of infectious mononucleosis. Am. Fam. Physician30(5), 195–199 (1984).
   PubMed Web of Science ®Google Scholar
• Imashuku S. Clinical features and treatment strategies of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Crit. Rev. Oncol. Hematol.44(3), 259–272 (2002).
   PubMed Web of Science ®Google Scholar
• Jenson HB. Acute complications of Epstein–Barr virus infectious mononucleosis. Curr. Opin. Pediatr.12(3), 263–268 (2000).
   PubMed Web of Science ®Google Scholar
• Connelly KP, DeWitt LD. Neurologic complications of infectious mononucleosis. Pediatr. Neurol.10(3), 181–184 (1994).
   PubMedGoogle Scholar
• Andersson J. Clinical and immunological considerations in Epstein–Barr virus-associated diseases. Scand. J. Infect. Dis.100(Suppl.), 72–82 (1996).
   Google Scholar
• Cohen JI. Benign and malignant Epstein–Barr virus-associated B-cell lymphoproliferative diseases. Semin. Hematol.40(2), 116–123 (2003).
   PubMedGoogle Scholar
• Markin RS. Manifestations of Epstein–Barr virus-associated disorders in liver. Liver14(1), 1–13 (1994).
   PubMedGoogle Scholar
• Linde A. Diagnosis of Epstein–Barr virus-related diseases. Scand. J. Infect. Dis.100(Suppl.), 83–88 (1996).
   Google Scholar
• Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J. Clin. Microbiol.42(8), 3381–3387 (2004).
   PubMed Web of Science ®Google Scholar
• Gartner BC, Hess RD, Bandt D et al. Evaluation of four commercially available Epstein–Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin. Diagn. Lab. Immunol.10(1), 78–82 (2003).
   PubMedGoogle Scholar
• Pitetti RD, Laus S, Wadowsky RM. Clinical evaluation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein–Barr virus infection in children. Pediatr. Infect. Dis. J.22(8), 736–739 (2003).
   PubMed Web of Science ®Google Scholar
• Candy B, Chalder T, Cleare AJ, Wessely S, Hotopf M. What advice do patients with infectious mononucleosis report being given by their general practitioner? J. Psychosom. Res.58(5), 435–437 (2005).
   PubMedGoogle Scholar
• Dalrymple W. Infectious mononucleosis. 2. Relation of bed rest and activity to prognosis. Postgrad. Med.35, 345–349 (1964).
   PubMedGoogle Scholar
• Candy B, Chalder T, Cleare AJ, Wessely S, White PD, Hotopf M. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br. J. Gen. Pract.52(483), 844–851 (2002).
   PubMed Web of Science ®Google Scholar
• Thompson SK, Doerr TD, Hengerer AS. Infectious mononucleosis and corticosteroids: management practices and outcomes. Arch. Otolaryngol. Head Neck Surg.131(10), 900–904 (2005).
   PubMedGoogle Scholar
• Disney FA. Corticosteroids for infectious mononucleosis. Pediatr. Infect. Dis. J.7(11), 820–821 (1988).
   PubMedGoogle Scholar
• Collins M, Fleisher G, Kreisberg J, Fager S. Role of steroids in the treatment of infectious mononucleosis in the ambulatory college student. J. Am. Coll. Health33(3), 101–105 (1984).
   PubMedGoogle Scholar
• Tynell E, Aurelius E, Brandell A et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J. Infect. Dis.174, 324–331 (1996).
   PubMed Web of Science ®Google Scholar
• Brandfonbrener A, Epstein A, Wu S, Phair J. Corticosteroid therapy in Epstein–Barr virus infection. Effect on lymphocyte class, subset, and response to early antigen. Arch. Intern. Med.146(2), 337–339 (1986).
   PubMed Web of Science ®Google Scholar
• Andersson J, Ernberg I. Management of Epstein–Barr virus infections. Am. J. Med.85(2A), 107–115 (1988).
   PubMed Web of Science ®Google Scholar
• Roy M, Bailey B, Amre DK, Girodias JB, Bussieres JF, Gaudreault P. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Arch. Pediatr. Adolesc. Med.158(3), 250–254 (2004).
   PubMedGoogle Scholar
• Peter J, Ray CG. Infectious mononucleosis. Pediatr. Rev.19(8), 276–279 (1998).
   PubMedGoogle Scholar
• Portman M, Ingall D, Westenfelder G, Yogev R. Peritonsillar abscess complicating infectious mononucleosis.J. Pediatr.104(5), 742–744 (1984).
   PubMedGoogle Scholar
• Fleisher GR, Collins M, Fager S. Humoral immune response in infectious mononucleosis. Late emergence of anti-EA(R) and the effects of corticosteroid therapy. J. Adolesc. Health Care6(6), 424–428 (1985).
   PubMedGoogle Scholar
• Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein–Barr virus DNA replication. J. Virol.34(2), 560–568 (1980).
   PubMed Web of Science ®Google Scholar
• Datta AK, Colby BM, Shaw JE, Pagano JS. Acyclovir inhibition of Epstein–Barr virus replication. Proc. Natl. Acad. Sci. USA77(9), 5163–5166 (1980).
   PubMed Web of Science ®Google Scholar
• Miller CS, Avdiushko SA, Kryscio RJ, Danaher RJ, Jacob RJ. Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. J. Clin. Microbiol.43(5), 2173–2180 (2005).
   PubMed Web of Science ®Google Scholar
• Simon MW, Deeter RG, Shahan BS. The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double-blind, placebo-controlled study. Int. Pediatr.18, 164–169 (2003).
   Google Scholar
• Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand. J. Infect. Dis.31(6), 543–547 (1999).
   PubMed Web of Science ®Google Scholar
• Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs52(1), 17–32 (1996).
   PubMed Web of Science ®Google Scholar
• Goldani LZ. Treatment of severe infectious mononucleosis with famciclovir. J. Infect.44(2), 92–93 (2002).
   PubMedGoogle Scholar
• Diez R, Diaz C, Frauca E et al. Valganciclovir in EBV infection after pediatric liver transplantation. Paper presented at World Transplant Congress, Boston, MA (2006).
   Google Scholar
• Simon MW, Fish DN, Deeter RG. Pharmacokinetics and safety of valaciclovir in children with Epstein–Barr virus illness. Drugs RD3(6), 365–373 (2002).
   PubMedGoogle Scholar
• Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein–Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation64(6), 848–852 (1997).
   PubMed Web of Science ®Google Scholar
• Garamendi I, Montejo M, Cancelo L et al. Encephalitis caused by Epstein–Barr virus in a renal transplant recipient. Clin. Infect. Dis.34(2), 287–288 (2002).
   PubMedGoogle Scholar
• Dellemijn PL, Brandenburg A, Niesters HG, van den Bent MJ, Rothbarth PH, Vlasveld LT. Successful treatment with ganciclovir of presumed Epstein–Barr meningo-encephalitis following bone marrow transplant. Bone Marrow Transplant.16(2), 311–312 (1995).
   PubMed Web of Science ®Google Scholar
• Adams LA, Deboer B, Jeffrey G, Marley R, Garas G. Ganciclovir and the treatment of Epstein–Barr virus hepatitis. J. Gastroenterol. Hepatol.21(11), 1758–1760 (2006).
   PubMed Web of Science ®Google Scholar
• Meerbach A, Holy A, Wutzler P, De Clercq E, Neyts J. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein–Barr virus replication. Antivir. Chem. Chemother.9(3), 275–282 (1998).
   PubMed Web of Science ®Google Scholar
• Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein–Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res.62(3), 121–123 (2004).
   PubMed Web of Science ®Google Scholar
• Williams-Aziz SL, Hartline CB, Harden EA et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother.49(9), 3724–3733 (2005).
   PubMed Web of Science ®Google Scholar
• Gershburg E, Hong K, Pagano JS. Effects of maribavir and selected indolocarbazoles on Epstein–Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob. Agents Chemother.48(5), 1900–1903 (2004).
   PubMed Web of Science ®Google Scholar
• Gershburg E, Pagano JS. Epstein–Barr virus infections: prospects for treatment. J. Antimicrob. Chemother.56(2), 277–281 (2005).
   PubMed Web of Science ®Google Scholar
• Hartline CB, Harden EA, Williams-Aziz SL, Kushner NL, Brideau RJ, Kern ER. Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res.65(2), 97–105 (2005).
   PubMed Web of Science ®Google Scholar
• Pagano JS, Blaser M, Buendia MA et al. Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol.14(6), 453–471 (2004).
   PubMed Web of Science ®Google Scholar
• Krilov LR, Fisher M, Friedman SB, Reitman D, Mandel FS. Course and outcome of chronic fatigue in children and adolescents. Pediatrics102(2 Pt 1), 360–366 (1998).
   PubMed Web of Science ®Google Scholar
• Petersen I, Thomas JM, Hamilton WT, White PD. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. QJM99(1), 49–55 (2006).
   PubMed Web of Science ®Google Scholar
• Bennett BK, Hickie IB, Vollmer-Conna US et al. The relationship between fatigue, psychological and immunological variables in acute infectious illness. Aust. NZJ Psychiatry32(2), 180–186 (1998).
   PubMed Web of Science ®Google Scholar
• White PD, Thomas JM, Kangro HO et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet358(9297), 1946–1954 (2001).
   PubMed Web of Science ®Google Scholar
• Vernon SD, Whistler T, Cameron B, Hickie IB, Reeves WC, Lloyd A. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus. BMC Infect. Dis.6, 15 (2006).
   PubMed Web of Science ®Google Scholar
• Vernon SD, Nicholson A, Rajeevan M et al. Correlation of psycho-neuroendocrine-immune (PNI) gene expression with symptoms of acute infectious mononucleosis. Brain Res.1068(1), 1–6 (2006).
   PubMedGoogle Scholar
• Katz BZ. Update on chronic fatigue syndrome and Epstein–Barr virus. Pediatr. Ann.31(11), 741–744 (2002).
   PubMed Web of Science ®Google Scholar
• Vernon SD, Whistler T, Aslakson E, Rajeevan M, Reeves WC. Challenges for molecular profiling of chronic fatigue syndrome. Pharmacogenomics7(2), 211–218 (2006).
   PubMed Web of Science ®Google Scholar
• Okano M, Kawa K, Kimura H et al. Proposed guidelines for diagnosing chronic active Epstein–Barr virus infection. Am. J. Hematol.80(1), 64–69 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura H. Pathogenesis of chronic active Epstein–Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev. Med. Virol.16(4), 251–261 (2006).
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Askling J, Rostgaard K et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N. Engl. J. Med.349(14), 1324–1332 (2003).
   PubMed Web of Science ®Google Scholar
• Chang ET, Zheng T, Weir EG et al. Childhood social environment and Hodgkin’s lymphoma: new findings from a population-based case–control study. Cancer Epidemiol. Biomarkers Prev.13(8), 1361–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer RM, Ambinder RF, Stroobants S. Hodgkin’s lymphoma: evolving concepts with implications for practice. Hematology (Am. Soc. Hematol. Educ. Program), 184–202 (2004).
   PubMedGoogle Scholar
• Glaser SL, Keegan TH, Clarke CA et al. Exposure to childhood infections and risk of Epstein–Barr virus – defined Hodgkin’s lymphoma in women. Int. J. Cancer115(4), 599–605 (2005).
   PubMedGoogle Scholar
• Tao Q, Young LS, Woodman CB, Murray PG. Epstein–Barr virus (EBV) and its associated human cancers – genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci.11, 2672–2713 (2006).
   PubMed Web of Science ®Google Scholar
• Sauce D, Larsen M, Curnow SJ et al. EBV-associated mononucleosis leads to long-term global deficit in T cell responsiveness to IL-15. Blood108(1), 8–11 (2006).
   Google Scholar
• Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol.26(1), 56–64 (2005).
   PubMed Web of Science ®Google Scholar
• Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein–Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl Acad. Sci. USA95(20), 11963–11968 (1998).
   PubMed Web of Science ®Google Scholar
• Portis T, Dyck P, Longnecker R. Epstein–Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood102(12), 4166–4178 (2003).
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Lennette ET et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA286(24), 3083–3088 (2001).
   PubMed Web of Science ®Google Scholar
• Levin LI, Munger KL, Rubertone MV et al. Temporal relationship between elevation of Epstein–Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA293(20), 2496–2500 (2005).
   PubMed Web of Science ®Google Scholar
• Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol.59(3), 499–503 (2006).
   PubMed Web of Science ®Google Scholar
• McClain MT, Poole BD, Bruner BF, Kaufman KM, Harley JB, James JA. An altered immune response to Epstein–Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum.54(1), 360–368 (2006).
   PubMedGoogle Scholar
• Poole BD, Scofield RH, Harley JB, James JA. Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity39(1), 63–70 (2006).
   PubMed Web of Science ®Google Scholar
• Woodberry T, Suscovich TJ, Henry LM et al. Differential targeting and shifts in the immunodominance of Epstein–Barr virus-specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis.192(9), 1513–1524 (2005).
   PubMedGoogle Scholar
• Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein–Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev.170, 49–64 (1999).
   PubMed Web of Science ®Google Scholar
• Shope TC. Prevention of Epstein–Barr virus (EBV)-induced infection in cotton-topped marmosets by human serum containing EBV neutralizing activity. IARC Sci. Publ.1975(11 Pt 2), 153–159.
   Google Scholar
• Pither RJ, Zhang CX, Shiels C, Tarlton J, Finerty S, Morgan AJ. Mapping of B-cell epitopes on the polypeptide chain of the Epstein–Barr virus major envelope glycoprotein and candidate vaccine molecule gp340. J. Virol.66(2), 1246–1251 (1992).
   PubMedGoogle Scholar
• Gu SY, Huang TM, Ruan L et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand.84, 171–177 (1995).
   PubMedGoogle Scholar
• Emini EA, Schleif WA, Silberklang M, Lehman D, Ellis RW. Vero cell-expressed Epstein–Barr virus (EBV) gp350/220 protects marmosets from EBV challenge. J. Med. Virol.27(2), 120–123 (1989).
   PubMed Web of Science ®Google Scholar
• Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein–Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine12(13), 1180–1184 (1994).
   Google Scholar
• Denis M, Haumont H, Bolen A. Vaccination against Epstein–Barr virus (EBV): report of Phase II studies using recombinant viral glycoprotein gp350 in healthy adults. Paper presented at the 11th Biennial Conference of the International Association for Research on Epstein–Barr virus and Associated Diseases, September, Regensburg, Germany (2004).
   Google Scholar
• Ponsonby AL, van der Mei I, Dwyer T et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA293(4), 463–469 (2005).
   PubMedGoogle Scholar
• Grulich AE, Vajdic CM, Kaldor JM et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J. Natl Cancer Inst.97(8), 587–594 (2005).
   PubMedGoogle Scholar
• Andersson J. An overview of Epstein–Barr virus: from discovery to future directions for treatment and prevention. Herpes7(3), 76–82 (2000).
   PubMedGoogle Scholar